(NASDAQ: VAXX) Vaxxinity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Vaxxinity's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VAXX's revenue for 2024 to be $1,698,418,966, with the lowest VAXX revenue forecast at $1,698,418,966, and the highest VAXX revenue forecast at $1,698,418,966. On average, 1 Wall Street analysts forecast VAXX's revenue for 2025 to be $3,903,828,667, with the lowest VAXX revenue forecast at $3,903,828,667, and the highest VAXX revenue forecast at $3,903,828,667.
In 2026, VAXX is forecast to generate $7,871,031,176 in revenue, with the lowest revenue forecast at $7,871,031,176 and the highest revenue forecast at $7,871,031,176.